Alexion has said it can ramp up production if the drug works in trials but what it has not mentioned is its cost: Ultomiris is hugely expensive when used in rare diseases, costing several thousand ...

Alexion has lashed out at NICE after the cost-effectiveness watchdog decided to limit the use of Strensiq, an ultra-rare disease treatment. Strensiq (asfotase alpha) is for the rare disease ...

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines.

Cardiac surgery-associated acute kidney injury (CSA-AKI) occurs in ≥50% of patients with chronic kidney disease (CKD) undergoing cardiac surgery with cardiopulmonary bypass (CPB) 2. At Alexion ...